Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Trulicity Summary of Product Characteristics (SmPC)
Trulicity® (dulaglutide): Hypersensitivity Including Anaphylactic Reactions and Angioedema
Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with dulaglutide.
Dulaglutide is contraindicated in patients with a known hypersensitivity to dulaglutide or to any of the excipients.1
Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported in patients treated with dulaglutide and other glucagon-like peptide-1 receptor agonists. 2
If a hypersensitivity reaction occurs, discontinue dulaglutide, treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity reaction to dulaglutide.2
Clinical Study Experience
In the phase II and phase III clinical studies, systemic hypersensitivity events (e.g., urticaria, oedema) were reported in 0.5 % of patients receiving dulaglutide.1
Postmarketing Experience
There have been reports of anaphylactic reactions and angioedema during postapproval use of dulaglutide.2
Reporting rates of anaphylactic reactions have been very rarely reported in patients receiving dulaglutide, <0.01%.2
1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
GLP-1 RA = glucagon-like peptide-1 receptor agonist
Date of Last Review: April 06, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays